← TickerEye

0I7E.LDaVita Inc.

Stock·LSE·£

£229,68+3.31%
...
Day High£229,94
Day Low£219,84
Volume806

About

DaVita Inc. specializes in delivering vital kidney dialysis treatments to individuals afflicted with chronic kidney failure. The company manages numerous outpatient dialysis clinics, where it not only conducts dialysis sessions but also offers essential laboratory testing services. Its comprehensive offerings extend to outpatient, hospital inpatient, and at-home hemodialysis. Furthermore, DaVita operates its own clinical laboratories, performing standard dialysis-related tests and other prescribed analyses for ESRD patients, alongside providing management and administrative support to its network of outpatient centers. Beyond core dialysis, DaVita delivers a suite of integrated care services, including disease management for approximately 23,000 patients (within both risk-based and other integrated arrangements), vascular access procedures, clinical research initiatives, physician consultation, and holistic kidney care programs. By the close of 2021, DaVita maintained a substantial presence, with 2,815 outpatient dialysis facilities across the United States serving around 203,100 patients, and an additional 339 centers in 10 international markets supporting roughly 39,900 patients. In the U.S., it also delivered acute inpatient dialysis services, complete with laboratory support, in approximately 850 hospitals. Originally incorporated in 1994 and headquartered in Denver, Colorado, the company adopted its current name, DaVita Inc., in September 2016, having previously operated as DaVita HealthCare Partners Inc.

www.davita.com

Key Statistics

Market Cap
16.36B
EPS
9.72
Dividend Yield
0.00%
Beta
0.91
P/B
-12.94
Return on Equity
-114.7%
Sector
Healthcare
Industry
Medical - Care Facilities
CEO
Javier J. Rodriguez
Employees
76,000
IPO Date
2018-01-29
Country
US

Track live with TickerEye

See 0I7E.L price live on your physical desk display. Set alerts with iOS & Android apps.